---
title: Improve recognizing emotions on medication
nct_id: NCT06884722
phase: NA
status: RECRUITING
sponsor: Hospices Civils de Lyon
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06884722"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06884722"
last_fetched: "2026-05-10T14:07:11.216Z"
source: "Parkinson's Pathways (curated)"
---
# Improve recognizing emotions on medication

**Goal (in five words):** Improve recognizing emotions on medication

**Official Title:** Social Perception and Dopaminergic Modulation in Patients With Parkinson's Disease: a Functional MRI Study (Park Social-E-Motion)

**Trial ID:** [NCT06884722](https://clinicaltrials.gov/study/NCT06884722)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Hospices Civils de Lyon
- **Target Enrollment:** 83 participants
- **Start Date:** 2025-07-15
- **Completion Date:** 2027-04
- **Conditions:** Social Perception in Parkinson's Disease
- **Interventions:** Behavioral task of social perception (stage 1), Functional magnetic resonance imaging: 3 Tesla magnetic resonance imaging (stage 2), Neurological and neuropsychological assessments, Neurological assessments of Parkinson's disease symptoms and caregiver burden
- **Intervention Types:** BEHAVIORAL, OTHER

## Summary For Families

The goal is to understand how Parkinson's and dopamine treatment change the way people perceive social cues like faces and emotions, because those social and emotional difficulties can be common and distressing. Participants complete simple social perception tasks while researchers record brain activity with 3 Tesla fMRI, comparing responses in people on their usual dopaminergic medications, since those drugs boost brain dopamine and can alter emotional and social processing; the study also includes neurological, neuropsychological, and caregiver burden assessments. Looking for people aged 30 to 75 who have had Parkinson's for at least 3 years, are taking dopaminergic treatment, and do not have disabling cognitive impairment (MoCA 26 or higher); healthy volunteers are also recruited for the imaging part.

## Eligibility

- **Minimum age:** 30 Years
- **Maximum age:** 75 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Male or female between 30 and 75 years of age
* Freely-given informed consent to participate to this study (written form)
* Affiliated with a social security system or equivalent;
* Person diagnosed with Parkinson's disease according to MDS-UPDRS criteria for at least 3 years and receiving dopaminergic treatment (e.g. : LEVODOPA, CARBIDOPA, BENZERASIDE, ENTACAPONE, MODOPAR, SINEMET, STALEVO, PRAMIPEXOLE, SIFROL, ROPINIROLE, REQUIP ; ROTIGOTINE, NEUPRO, PIRIBEDIL, TRIVASTAL, RASAGILINE, AZILECT, CONTAM, AMANTADINE, MANTADIX, APOMORPHINE, APOKINON, DOPACEPTIN, FOSLEVODOPA, FOSCARBIDOPA, SCYOVA) (for patients only)
* Effective contraception for women of childbearing age or post-menopausal women (only for patients and healthy volunteers in stage 2 "imaging")
* Requiring dopa testing as part of routine care (only for patients in stage 2 "imaging")
* No disabling cognitive impairment (MOCA score ≥ 26)
* No diagnosis of chronic disease associated with disability (only for healthy volunteers)

Exclusion Criteria:

* Contraindication to MRI (only for patients and healthy volunteers in step 2 "imaging"):

  * Wearing a pacemaker not approved for 3 Tesla MRI
  * Presence of intracerebral ferromagnetic or magnetizable material
  * Presence of intraocular ferromagnetic or magnetizable foreign bodies
  * Presence of non-removable ferro-magnetic or magnetizable foreign bodies in the cephalic region
  * Claustrophobia
* History of head trauma with loss of consciousness lasting more than 30 min (only for patients and healthy volunteers in step 2 "imaging")
* Participant not agreeing to be informed in the event of incidental discovery of an abnormality on MRI (only for patients and healthy volunteers in stage 2 "imaging")
* Tremor or disabling dyskinesias preventing MRI (only for patients in stage 2)
* Having exceeded the annual amount of compensation allowed for participation in research protocols (only for healthy volunteers)
* Pregnant, parturient or breast-feeding women
* Persons deprived of liberty by judicial or administrative decision
* Persons under psychiatric care
* Persons admitted to a health or social institution for purposes other than research
* Adults under legal protection (guardianship, curatorship)
* Participants in other intervention research involving a period of exclusion still in progress at the time of pre-inclusion.
```

## Locations (1)

- Service de neurologie - troubles du mouvement et pathologies neuromusculaires, Hôpital neurologique Pierre Wertheimer/GHE, Bron, France _(45.7386, 4.9130)_
  - Stéphane PRANGE, MD, PhD — (CONTACT) — 472 357 222 — stephane.prange@chu-lyon.fr

## Central Contacts

- Stéphane PRANGE, MD, PhD — (CONTACT) — 472 357 222 — stephane.prange@chu-lyon.fr
- Elise METEREAU — (CONTACT) — 427 856 208 — elise.metereau@chu-lyon.fr

---

*Canonical: https://parkinsonspathways.com/trial/NCT06884722*  
*HTML version: https://parkinsonspathways.com/trial/NCT06884722*  
*Source data: https://clinicaltrials.gov/study/NCT06884722*